FREE Daily Stock Alerts From Stock-PR.com
Crown Equity Holdings Inc. (OTCPK:CRWE)
Crown Equity Holdings Inc. is pleased to report its financial results for the nine month period ending September 30, 2010. Revenue for the nine months totaled $1,073,383 compared to $418,959 during 2009. CRWE incurred an operating loss of $54,527 for the nine months ending September 30, 2010 compared to an operating loss of $36,923 during the same period in 2009. Net loss of $343,049 for the nine months ending September 30, 2010 compared to a net loss of $29,379 for the same period in 2009. The net loss in 2010 was attributed mostly to an unrealized loss of $307,544 on securities held by CRWE .
"Our continued progress in operations including an operating profit of $7,251 during the last quarter shows a continued growth in our business," commented Kenneth Bosket, President & CEO of Crown Equity Holdings Inc. "Not only do our financial results show strong growth during this year but our continued investment in infrastructure will support our future growth," stated Bosket.
CRWE is extending its internet footprint internationally to include the following countries; Argentina, Brazil, Canada, China, France, Germany, Hong Kong, India, Indonesia, Italy, Japan, Korea, Malaysia, Mexico, New Zealand, Pakistan, Russia, Singapore, Spain, South Africa, Taiwan, United Arab Emirates and United Kingdom.
Pros claim banner ads are classified as the most beneficial tool for the reason that create the actual brand and make potential customers. Given that online advertising is certainly cheaper as compared with traditional print advertising, TV as well as direct email, the internets funnel will work better in a down economic system.
Advertising for the duration of all of market circumstances is crucial into the foreseeable future achievements regarding providers.
Companies that pursue to advertise irrespective of economic occasions use a competitively priced advantage over businesses that cut their advert finances.
Micromet, Inc. (Nasdaq:MITI) announced on December 6, 2010 the presentation of updated results from an on-going Phase 1 trial of the Company's lead product candidate blinatumomab (MT103) in patients with relapsed non-Hodgkin's lymphoma (NHL). Results of the expanded experience suggest that blinatumomab continues to produce a high response rate and duration of response in a number of different NHL subtypes. Among patients who received the target dose of 60 micrograms per meter squared, 82% (18 of 22) achieved an objective response, including 4 out of 5 mantle cell lymphoma (MCL) patients. Blinatumomab is the first of a new class of agents called BiTEÂ® antibodies, designed to harness the body's T cells to kill cancer cells. The data were reported in a poster presentation (abstract # 2880) yesterday at the 52nd American Society of Hematology (NYSE:ASH) Annual Meeting in Orlando, FL.
Micromet Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of antibodies for the treatment of cancer, inflammation, and autoimmune diseases. Its product development pipeline includes novel antibodies generated with its proprietary BiTE antibody platform, as well as conventional monoclonal antibodies.
Sequenom Inc. (Nasdaq:SQNM) announced common stock offering that priced on December 2, 2010 have exercised in full an option to purchase an additional 2,100,000 shares of its common stock. Including the additional shares being purchased, the offering will total 16,100,000 shares at a public offering price of $6.00 per share, resulting in aggregate gross proceeds to Sequenom of $96.6 million (before deducting underwriting discounts and commissions and other estimated offering expenses payable by Sequenom). Jefferies & Company, Inc. is acting as sole book-running manager for the offering, and Lazard Capital Markets LLC and Piper Jaffray & Co. are acting as co-managers for the offering. The offering is expected to close on or about December 7, 2010, subject to customary closing conditions.
Sequenom, Inc. provides products, services, diagnostic testing, applications, and genetic analysis products that translate the results of genomic science into solutions for biomedical research, translational research, molecular medicine applications, and agricultural and livestock. The company operates in two segments, Genetic Analysis and Molecular Diagnostics.
Exar Corp. (Nasdaq:EXAR) announced on December 6, 2010 the Express DX 1845 high-performance data security and reduction card. The DX 1845 provides a simple, power-efficient solution to secure and optimize data in enterprise applications. The new data security and reduction card offloads these tasks from the host microprocessor, freeing up valuable cycles to be applied to the application workload or reducing the type or number of microprocessors needed. By reducing the number of additional microprocessors needed the DX 1845 helps customers with power, cooling and capital expenditures, enabling a lower Total Cost of Ownership (NYSE:TCO). With the adoption of cloud computing, and increased requirements around protecting information, security is no longer just an issue to be handled in firewalls at the edge of the data center but needs to be addressed throughout the data center.
Exar Corporation, a fabless semiconductor company, together with its subsidiaries, engages in the design, contract manufacture, and sale of silicon, software, and subsystem solutions for industrial, telecom, networking, and storage applications. Its product portfolio includes power management and interface components, datacom products, storage optimization solutions, network security, and applied service processors.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Stock-PR.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold Stock-PR.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://stock-pr.com/disclaimer).Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.
Sign Up For Free Stock Alerts At http://stock-pr.com/signup
The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone.